Longitudinal multi-functional analysis identified responses of T cells, B cells, and monocytes as hallmarks of immunotherapy tolerance in patients with merkel cell carcinoma.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2023
Historique:
received: 13 04 2023
accepted: 21 10 2023
medline: 22 11 2023
pubmed: 20 11 2023
entrez: 20 11 2023
Statut: epublish

Résumé

Merkel cell carcinoma (MCC) is a neuroendocrine carcinoma originating in the skin. Studies are needed to determine the mechanisms of immune escape in patients with MCC, and malignant cell conditions that promote immune evasion. We used Single-cell RNA sequencing (scRNA-seq) to determine cellular features associated with MCC disease trajectory. A longitudinal multi-omics study was performed using scRNA-seq data of peripheral blood harvested from four-time points. Six major cell types and fifteen cell subgroups were identified and confirmed their presence by expression of characteristic markers. The expression patterns and specific changes of different cells at different time points were investigated. Subsequently, bulk RNA data was used to validate key findings. The dynamic characteristics of the cells were identified during the critical period between benign improvement and acquisition of resistance. Combined with the results of the validation cohort, the resistance program expressed in the relapse stage is mainly associated with T cell exhaustion and immune cell crosstalk disorder. Coinciding with immune escape, we also identified a decrease non-classical monocytes and an expansion of classical monocytes with features of high inflammation and immune deficiency. Changes in cellular status, such as depletion of T cells and dysregulation of B cell proliferation and differentiation, may lead to drug resistance in MCC patients. Meanwhile, the widespread decreased antigen presentation ability and immune disorders caused by deletion of MHC class II gene expression should not be ignored.

Identifiants

pubmed: 37983224
doi: 10.1371/journal.pone.0293922
pii: PONE-D-23-11186
pmc: PMC10659156
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0293922

Informations de copyright

Copyright: © 2023 Tao et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Cell. 2015 Nov 5;163(4):799-810
pubmed: 26544934
Viral Immunol. 2020 May;33(4):294-306
pubmed: 32326852
Clin Cancer Res. 2018 Mar 15;24(6):1260-1270
pubmed: 29127120
Immunol Cell Biol. 2017 Jan;95(1):33-41
pubmed: 27465674
Int J Mol Sci. 2021 Aug 12;22(16):
pubmed: 34445385
J Invest Dermatol. 2013 Jul;133(7):1879-89
pubmed: 23419694
BMC Bioinformatics. 2013 Jan 16;14:7
pubmed: 23323831
Nat Immunol. 2020 Jul;21(7):790-801
pubmed: 32424361
Cancer Immunol Res. 2013 Jul;1(1):54-63
pubmed: 24416729
Immunity. 2018 May 15;48(5):1029-1045.e5
pubmed: 29768164
Lancet Oncol. 2017 Dec;18(12):e731-e741
pubmed: 29208439
Science. 2008 Feb 22;319(5866):1096-100
pubmed: 18202256
J Clin Oncol. 2011 Apr 20;29(12):1539-46
pubmed: 21422430
Cancer Med. 2016 Sep;5(9):2294-301
pubmed: 27431483
Immunity. 2010 Mar 26;32(3):355-66
pubmed: 20226693
J Am Acad Dermatol. 2018 Mar;78(3):457-463.e2
pubmed: 29102486
Cell Res. 2020 Sep;30(9):745-762
pubmed: 32561858
Nat Rev Dis Primers. 2017 Oct 26;3:17077
pubmed: 29072302
Cancer Immunol Res. 2014 Nov;2(11):1071-9
pubmed: 25116754
Future Oncol. 2017 Jun;13(14):1263-1279
pubmed: 28350180
Biochim Biophys Acta. 2013 Feb;1831(2):276-81
pubmed: 23032787
Clin Cancer Res. 2019 Oct 1;25(19):5961-5971
pubmed: 31399473
Nat Biotechnol. 2018 Jun;36(5):411-420
pubmed: 29608179
Sci Rep. 2017 May 23;7(1):2290
pubmed: 28536458
N Engl J Med. 2016 Jun 30;374(26):2542-52
pubmed: 27093365
Nat Commun. 2018 Sep 24;9(1):3868
pubmed: 30250229
Nat Med. 2018 Jul;24(7):978-985
pubmed: 29942094
Int J Mol Sci. 2017 Dec 06;18(12):
pubmed: 29211042
Hum Pathol. 2016 Jun;52:190-6
pubmed: 26980039
Nat Commun. 2019 Aug 21;10(1):3763
pubmed: 31434891
Cell Rep. 2016 Jan 5;14(1):68-81
pubmed: 26725120
J Am Acad Dermatol. 2010 Nov;63(5):751-61
pubmed: 20646783
Cancer Res. 2012 Apr 15;72(8):2120-8
pubmed: 22389452
Sci Rep. 2016 Feb 23;6:21678
pubmed: 26902929
Science. 2017 Jul 28;357(6349):409-413
pubmed: 28596308
Cancer Res. 2013 Mar 15;73(6):1733-41
pubmed: 23288508
J Natl Compr Canc Netw. 2018 Jun;16(6):742-774
pubmed: 29891526
Science. 2015 Apr 3;348(6230):56-61
pubmed: 25838373
Mol Oncol. 2014 Sep 12;8(6):1132-9
pubmed: 25106088
Br J Cancer. 2017 Jan 17;116(2):260-264
pubmed: 27978533

Auteurs

Quyuan Tao (Q)

School of Basic Medical Science, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China.

Jia-Xin Du (JX)

School of Basic Medical Science, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China.

Shijing Zhang (S)

School of Basic Medical Science, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China.

Wenjia Lin (W)

School of Basic Medical Science, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China.

Yongxin Luo (Y)

School of Basic Medical Science, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China.

Ying Liu (Y)

School of Basic Medical Science, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China.

Jingyan Zeng (J)

Shenzhen Clinical College, Guangzhou University of Chinese Medicine, Guangzhou, China.

Xin-Lin Chen (XL)

School of Basic Medical Science, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH